Loading clinical trials...
Loading clinical trials...
Efficacy, Tolerability and Pharmacokinetic Comparison of Immune Globulin Intravenous (Human), 10% (GAMMAGARD LIQUID/KIOVIG) Administered Intravenously or Subcutaneously Following Administration of Recombinant Human Hyaluronidase (rHuPH20) in Subjects With Primary Immunodeficiency Diseases
Conditions
Interventions
Recombinant human hyaluronidase (rHuPH20)+ immune globulin intravenous (IGIV)
Recombinant human hyaluronidase (rHuPH20)+ immune globulin intravenous (IGIV)
Locations
14
United States
Cypress, California, United States
Irvine, California, United States
Los Angeles, California, United States
San Francisco, California, United States
Centennial, Colorado, United States
North Palm Beach, Florida, United States
Start Date
December 18, 2008
Primary Completion Date
November 11, 2010
Completion Date
November 11, 2010
Last Updated
May 19, 2021
NCT05755035
NCT03277313
NCT01218438
NCT01175213
Lead Sponsor
Baxalta now part of Shire
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions